ArticleFrontiers in oncology2025
Case Report: Apatinib combined with IMRT concurrent therapy achieves rapid response and significantly prolongs progression-free survival in elderly patients with inoperable locally advanced esophageal squamous cell carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) typically have a poor prognosis, and concurrent chemoradiotherapy is the primary treatment modality. However, elderly patients often exhibit lower completion rates of concurrent chemoradiotherapy due to multiple comorbidities and reduced treatment tolerance, which directly affects their prognosis. Although apatinib combined with radiotherapy has demonstrated synergistic potential in treating certain solid tumors, its efficacy in elderly patients with LA-ESCC remains unclear. This case report involves an elderly patient with unresectable LA-ESCC who was treated with apatinib combined with intensity-modulated radiation therapy, The patient had comorbidities, including hypertension and diabetes, and declined chemotherapy. We implemented a treatment regimen consisting of intensity-modulated radiation therapy combined with low-dose apatinib. After nine sessions of radiotherapy, the patient's dysphagia significantly improved, and follow-up computed tomography revealed marked tumor shrinkage. As of July 2024, the patient has achieved a progression-free survival of 71 months without experiencing severe (Grade III/IV) adverse reactions. Therefore, apatinib combined with radiotherapy suggests potential benefits as a concurrent treatment option for elderly patients with unresectable LA-ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.